The April 2026 New York Times analysis of a systematic review questioning anti-amyloid therapies for Alzheimer's captures an important scientific spat but misses the deeper story: even the newest approved drugs deliver only marginal clinical gains while reinforcing a flawed, profit-driven paradigm that has dominated neurodegeneration research for three decades. The piece notes that the review unfairly lumped failed agents like aducanumab with lecanemab and donanemab, yet it fails to scrutinize whether those newer drugs truly clear the clinical-meaningfulness bar or represent the best path forward.

Consider the pivotal Clarity AD phase 3 RCT (NEJM, 2023; n=1,795 early-stage patients, double-blind, 18-month duration). Lecanemab achieved a 27% relative reduction in cognitive decline on the CDR-SB scale versus placebo, yet this translated to an absolute difference of just 0.45 points on an 18-point scale. Multiple independent analyses have deemed this change below established thresholds for meaningful patient or caregiver benefit. The trial also documented amyloid-related imaging abnormalities (ARIA-E or ARIA-H) in 21.3% of treated participants, with 12.6% experiencing symptomatic cases including cerebral edema and microhemorrhages. Conflicts of interest were notable: several lead investigators reported financial ties to the manufacturer Eisai.

A similar pattern emerged in the TRAILBLAZER-ALZ 2 trial for donanemab (JAMA, 2023; n=1,736). While statistically significant, the slowing of progression again hovered in the modest range, with serious adverse events and treatment discontinuation rates that raise questions about net value given the $26,500 annual list price.

What the Times coverage largely overlooked is the stark contrast with prevention science. The 2024 Lancet Commission on dementia prevention, intervention, and care synthesized data from multiple large prospective cohorts (total sample sizes >50,000 across studies, including interventional RCTs on risk-factor modification). It estimates that 40% of dementia cases may be attributable to 14 modifiable risk factors ranging from midlife hypertension and physical inactivity to later-life social isolation and hearing loss. Unlike most anti-amyloid trials, this commission maintains strict independence from pharmaceutical funding.

This fresh analysis reignites debate by exposing how the amyloid hypothesis, despite repeated failures from solanezumab to gantenerumab, continues to command the lion's share of research dollars. The pattern is clear: billions invested, narrow surrogate endpoints met (amyloid clearance on PET), yet minimal translation to real-world functional improvement. Meanwhile, lifestyle interventions demonstrate stronger signals for actual risk reduction. RCTs of aerobic exercise in at-risk older adults (e.g., n=200–400 cohorts) show improvements in executive function and reduced hippocampal atrophy. Large observational studies on the MIND diet (Rush University Memory and Aging Project, n>1,000) report up to 53% lower Alzheimer's rates with high adherence.

The original coverage got wrong its narrow framing of "lumping" drugs. The real issue is not statistical cherry-picking but opportunity cost. Every healthcare dollar funneled into marginal anti-amyloid therapies is a dollar not spent scaling proven, low-cost wellness strategies targeting sleep, nutrition, movement, and vascular health. This crack in the dominant pharmaceutical approach could redirect the field toward prevention-first models that empower individuals rather than positioning them as lifelong consumers of high-cost monoclonals.

The evidence increasingly suggests Alzheimer's and related dementias are not solely amyloid-driven diseases but complex syndromes influenced by lifelong metabolic, inflammatory, and lifestyle factors. By synthesizing these sources, a clearer picture emerges: the modest benefits of current anti-amyloid drugs do not justify their risks, costs, or opportunity costs. A genuine paradigm shift toward rigorous, prevention-focused wellness strategies is not only warranted but overdue.